12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $40M | -$120M | 0.0% | -326.6% | -$135M | — | $65M |
| 2024 | $80M | -$65M | 0.0% | -104.1% | -$19M | — | $71M |
| 2023 | $250M | $132M | 0.0% | 48.8% | $75M | — | $69M |
| 2022 | $41M | -$46M | 0.0% | -124.3% | -$15M | — | $99M |
| 2021 | $37M | -$71M | 0.0% | -196.8% | -$55M | — | $117M |
| 2020 | $171M | $37M | 0.0% | 16.0% | -$109M | — | $104M |
| 2019 | $104M | -$44M | 0.0% | -49.5% | $41M | — | $86M |
| 2018 | $8M | -$88M | 0.0% | -1195.6% | -$20M | — | $47M |
| 2017 | $10M | -$71M | 0.0% | -709.1% | -$65M | — | $32M |
| 2016 | $14M | -$40M | 0.0% | -290.4% | -$48M | — | $37M |
| 2015 | — | -$30M | — | — | $40M | — | $31M |
| 2014 | — | -$16M | — | — | — | — | $7M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $3M | -$28M | 0.0% | -1167.4% | -$33M | — | $43M |
| Dec '25 | $15M | -$27M | 0.0% | -195.2% | -$31M | — | $65M |
| Sep '25 | $13M | -$28M | 0.0% | -228.9% | -$31M | — | $45M |
| Jun '25 | $5M | -$33M | 0.0% | -704.3% | -$34M | — | $44M |
| Mar '25 | $6M | -$31M | 0.0% | -536.0% | -$39M | — | $75M |
| Dec '24 | $6M | -$34M | 0.0% | -610.1% | -$15M | — | $71M |
| Sep '24 | $25M | -$9M | 0.0% | -56.0% | -$28M | — | $113M |
| Jun '24 | $30M | -$10M | 0.0% | -50.8% | -$33M | — | $76M |
| Mar '24 | $20M | -$11M | 0.0% | -82.9% | $57M | — | $143M |
| Dec '23 | -$9M | $56M | 0.0% | -572.3% | -$25M | — | $69M |
| Sep '23 | $5M | -$26M | 0.0% | -639.5% | -$22M | — | $65M |
| Jun '23 | $5M | -$22M | 0.0% | -523.9% | -$2M | — | $244M |
| Mar '23 | $150M | $124M | 0.0% | 81.7% | $123M | — | $268M |
| Dec '22 | -$2M | -$24M | 0.0% | 1584.7% | -$13M | — | $99M |
| Sep '22 | $41M | $18M | 0.0% | 35.2% | -$16M | — | $97M |
| Jun '22 | $712000 | -$19M | 0.0% | -2720.1% | -$20M | — | $78M |
| Mar '22 | $658000 | -$21M | 0.0% | -3244.7% | $34M | — | $132M |
| Dec '21 | $28M | $6M | 0.0% | 20.3% | $11M | — | $117M |
| Sep '21 | $1M | -$25M | 0.0% | -1696.8% | -$21M | — | $111M |
| Jun '21 | $1M | -$30M | 0.0% | -2106.5% | -$23M | — | $118M |
How the market has priced VYGR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Voyager Therapeutics, Inc.'s revenue has declined 25.1% per year. These are computed facts, not advice.
As of FY2025, Voyager Therapeutics, Inc. reported — of total debt against $65M of cash.
In FY2025, gross margin was —, operating margin -326.6%, and net margin -296.5%.
As of Jun '26, Voyager Therapeutics, Inc. traded at a price-to-earnings ratio of about 3.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.